BioCentury | Mar 20, 2021
Finance

Dallas TIL play leads Friday IPO trio: Data Byte

...is running Phase II trials of CBP-201, an anti-IL-4R mAb to treat atopic dermatitis, and CBP-307...
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

...desmoid tumors; and Eisai Co. Ltd. (Tokyo:4523) has CREBBP/CTNNB1...
...modulator E7386, which disrupts the interaction between CREBBP...
...– Cas-Br-M ecotropic retroviral transforming sequence bCREBBP (CBP...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...to start Phase III trials of CBP-201, an anti-IL-4R mAb to treat atopic dermatitis, and CBP-307...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...through a CNS-focused collaboration, and the Japanese pharma has rights to Prism’s E-7386. The oral CREBBP/CTNNB1...
...a REST inhibitor for an undisclosed CNS indication. Targets CTNNB1 - β-catenin CREBBP (CBP) - CREB binding protein...
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

...testing for hematological cancers and Phase I testing for solid tumors, and FT-7051, a preclinical CBP/p300...
...funds managed by Janus Henderson Investors and an undisclosed healthcare investment fund. Targets: CBP - CREB binding protein...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...a small molecule modulator of the CH1 domain of E1A binding protein p300 (EP300; p300)/CREB binding protein (CBP...
BioCentury | Jan 4, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

...Crohn's disease. CBP-307 is a second-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist and CBP-201...
...see "Connect Raises $20M Series A Round" ). Suzhou Connect Biopharmaceuticals Ltd., Taicang, China Elizabeth S. Eaton CBP-201 CBP-307 Suzhou...
BioCentury | Jan 3, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

...trials to treat ulcerative colitis and Crohn's disease. CBP-307 is a second-generation S1PR1 agonist and CBP-201...
...IL-4R (IL-4RA; CD124) - IL-4 receptor; S1PR1 (S1P1; EDG1) - Sphingosine 1-phosphate receptor 1 Elizabeth S. Eaton CBP-201 CBP-307 Suzhou...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

...West said the dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP...
...of working out the biology, the chemistry and having a decent commercial opportunity.” EP300 and CREBBP...
...through a combination of government funding and target discovery deals. Virginia Li, Assistant Editor CCS1477 CellCentric Ltd. CREB binding protein (CREBBP) (CBP) E1A...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...CCS1477 is a dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP...
Items per page:
1 - 10 of 75